Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Primary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has...

Full description

Saved in:
Bibliographic Details
Published in:Hematology/oncology and stem cell therapy 2019-12, Vol.12 (4), p.220-225
Main Authors: Atilla, Erden, Sahin, Ugur, Atilla, Pinar Ataca, Merter, Mustafa, Ozyurek, Elif, Ceyhan, Koray, Bozdag, Sinem Civriz
Format: Article
Language:English
Subjects:
Adult
Allogeneic stem cell transplantation
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - therapy
Graft versus leukemia effect
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Non-Hodgkin - diagnostic imaging
Lymphoma, Non-Hodgkin - therapy
Male
Primary central nervous system lymphoma
Recurrence
Tomography, X-Ray Computed
Transplantation, Homologous
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT.
ISSN:1658-3876
DOI:10.1016/j.hemonc.2018.02.001